Soleno Therapeutics, Inc. (SLNO)
After hours:
| Previous close | 47.64 |
| Open | 47.64 |
| Bid | 44.92 x 200 |
| Ask | 45.07 x 100 |
| Day's range | 42.60 - 47.64 |
| 52-week range | 3.69 - 53.82 |
| Volume | |
| Avg. volume | 408,146 |
| Market cap | 1.735B |
| Beta (5Y monthly) | -1.50 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.36 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 65.17 |
GlobeNewswireSoleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 and Recent Corporate Highlights Closed on approximately $158.7 million underwritten public offering of 3,450,000 shares of common stock at a public offering
Simply Wall St.While institutions invested in Soleno Therapeutics, Inc. (NASDAQ:SLNO) benefited from last week's 4.8% gain, private equity firms stood to gain the most
Key Insights Significant control over Soleno Therapeutics by private equity firms implies that the general public has...
- GlobeNewswire
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing of the underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $46.00 per share. The gross proceeds of the public offering are expected to be approximately $138.0 million, before deducting under
